Original ArticleClinical Outcomes and Cost Analysis of PreserFlo versus Trabeculectomy for Glaucoma Management in the United Kingdom
Keywords
Abbreviations and Acronyms
Cited by (0)
Supplemental material available at www.ophthalmologyglaucoma.org.
Interim results of this study were presented at the International Congress on Glaucoma Surgery (2020), European Glaucoma Society Congress (2020), and the UK Eire Glaucoma Society Conference (2022).
Disclosure(s):
All authors have completed and submitted the ICMJE disclosures form.
The authors made the following disclosures:
I.R.: Consulting fees – iSTAR Medical, TTP (The Technology Partnership); Lecture fees – Santen; Travel expenses – iSTAR Medical, The Apperta Foundation; Advisory board member – Altacor; Committee member – NICE (National Institute for Health and Care excellence) glaucoma guideline update committee.
G.L.: Financial support – AbbVie, Aerie; Leadership – Deputy Chair, NAMinG Trial Management Committee/Group; Services – Glaukos, Rayner.
C.B.: Lecture fees – Santen.
E.C.: Consulting fees – Santen.
K.S.L.: Consultanting fees – Santen; Lecture fees – Santen.
SL: Lecture fees – Santen.
HUMAN SUBJECTS: Human subjects were included in this study. This study adhered to the tenets of the Declaration of Helsinki. A Health Research Authority decision tool deemed ethical approval was not required and the study was registered as an audit at each hospital trust (STH 10536, KCH GL001)
No animal subjects were used in this study.
Author Contributions:
Conception and design: Van Lancker, Abu-Bakra, Barwood, Combe, Kulkarni, Lim, Low
Analysis and interpretation: Van Lancker, Barwood, Combe, Lim, Low
Data collection: Van Lancker, Saravanan, Reid, Quijano, Low
Obtained funding: N/A
Overall responsibility: Van Lancker, Saravanan, Abu-Bakra, Reid, Quijano, Goyal, Rodrigues, Lascaratos, Trikha, Barwood, Combe, Kulkarni, Lim, Low